Modulux3d

At Modulux3D, we are redefining how new medicines and consumer products are tested before reaching patients and consumers. Born from cutting-edge research at Goethe University Frankfurt and the EU Horizon projects BRIGHTER and B-BRIGHTER, Modulux3D develops next-generation 3D bioprinting and AI-driven tissue model platforms that replicate human biology with unprecedented precision and longevity. Our flagship technology, the LUMINATE 3D bioprinter, fabricates complex, high-resolution tissue constructs (e.g, skin, liver, gut) using advanced light-sheet printing and adaptive AI quality control. Combined with our proprietary OptiPrintAI software (Distr@l funded), we enable fully automated quality control and reproducible tissue production, setting new standards for predictive, regulatory-ready in vitro testing. Why we’re different: Long-lived, physiologically accurate models that mimic real human tissues for weeks (supporting chronic exposure and recovery studies). AI-based quality control ensures every construct meets strict reproducibility and compliance criteria, addressing one of the biggest limitations in current 3D culture technologies. Modular hardware ecosystem: printers, organ models, and analytics — that integrates seamlessly into pharma and consumer-care R&D workflows. Regulatory alignment with OECD and ISO test guidelines bridging the gap between research and regulatory acceptance. By combining biophotonics, tissue engineering, and artificial intelligence, we empower pharmaceutical and consumer goods companies to replace unreliable animal testing with human-relevant, high-throughput models, ultimately bringing safer, more effective therapies to patients faster.